美银研究报告指，再鼎医药(09688.HK) (ZLAB.US) 日前公布有关ZL-1310的正面数据，加上美国FDA已授出“快速通道认证”(Fast Track Designation)，集团计划今年下半年开展第二类小细胞肺癌(2L SCLC)的第三阶段关键研究。基于以上临床进展，该行将集团2027年收入及净利润预测分别上调2.5%及14%，港股目标价由25.27港元升至29.61港元，美股目标价由32.6美元升至38.2美元，但重申“中性”评级，因核心产品的增长放缓。(ss/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-06-06 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.